At this year’s BIO CEO and Investor Conference in New York, I had the opportunity to meet Annalisa Jenkins, EVP and head of global R&D, Merck Serono. Jenkins has been busy working on a game-changing, singlesource CRO collaboration model with Quintiles. Understanding how and why she did it first requires insight into the leadership approach of her risk-enabling CEO, Belén Garijo (see page 24), followed by Jenkins’ detailed explanation of creating the model, along with some pretty good advice on building game-changing collaborations (see page 30). Finalizing this collaboration model won’t make her schedule any less busy; in fact, it just got busier.
On the day of our meeting, the Healthcare Businesswomen’s Association (HBA) publicized Jenkins as a 2014 Woman Of The Year (WOTY). Just two weeks later, TransCelerate BioPharma announced Jenkins as the new chairwoman of its board of directors. When you combine her positions with TransCelerate and HBA along with her advisory roles with the Center for Talent Innovation (CTI) and PhRMA, you get a sense for her willingness to engage outside her own company. This is a pivotal first step toward embracing one of our industry’s major trends — the new innovation ecosystem, which is where Jenkins anticipates the next wave of life sciences industry R&D innovations will come from. She is not alone in her opinion.